Alnylam
Pharmaceuticals, Inc. ALNY announced today new results from its ongoing Phase 2 open-label
extension (OLE) studies with patisiran and revusiran, investigational
RNAi therapeutics targeting transthyretin (TTR) for the treatment of
TTR-mediated amyloidosis (ATTR amyloidosis). These new
clinical data were presented at the 1st European
Congress on Hereditary ATTR amyloidosis (EC-ATTR) held November 2 – 3,
2015 in Paris. Data from the patisiran Phase 2 OLE study provided
continued evidence following 18 months of dosing that patisiran has the
potential to halt neuropathy progression in patients with Familial
Amyloidotic Polyneuropathy (FAP). The company is announcing today that
it expects to complete enrollment in the APOLLO Phase 3 trial of
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in